Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 30;12(12):2996.
doi: 10.3390/diagnostics12122996.

N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer

Mingyang Ma  1 , Tong Ye  1 , Jiewei Wang  1 , Haiying Zhao  1 , Shutian Zhang  1 , Peng Li  1 , Guiping Zhao  1
Affiliations
Review

N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer

Mingyang Ma et al. Diagnostics (Basel). .

Abstract

N6-methyladenosine (m6A) modification remains the most pivotal epigenetic modification on RNA. As we know, m6A not only affects physiological processes but is also involved in carcinoma. Noncoding RNAs play an indispensable role in the occurrence and development of carcinoma. However, a large amount of research is focused on mRNA currently. Insufficient research has been done on the relationship between noncoding RNA (ncRNA) methylation and cancer. Therefore, this review aims to introduce the theoretical knowledge of m6A modification in noncoding RNA, discuss its function in tumorigenesis and progression, and ultimately summarize its potential clinical applications.

Keywords: N6-methyladenosine; cancer; noncoding RNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study.

Figures

Figure 1
Figure 1
The interaction between miRNA and its m6A regulators.
Figure 2
Figure 2
The interaction between lncRNA and its m6A regulators.
Figure 3
Figure 3
The interaction between circRNA and its m6A regulators.
See this image and copyright information in PMC

References

    1. Crick F. Central dogma of molecular biology. Nature. 1970;227:561–563. doi: 10.1038/227561a0. - DOI - PubMed
    1. Matsui M., Corey D.R. Non-coding RNAs as drug targets. Nat. Rev. Drug Discov. 2017;16:167–179. doi: 10.1038/nrd.2016.117. - DOI - PMC - PubMed
    1. Hulshoff M.S., Del Monte-Nieto G., Kovacic J., Krenning G. Non-coding RNA in endothelial-to-mesenchymal transition. Cardiovasc. Res. 2019;115:1716–1731. doi: 10.1093/cvr/cvz211. - DOI - PMC - PubMed
    1. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011;12:861–874. doi: 10.1038/nrg3074. - DOI - PubMed
    1. Desrosiers R., Friderici K., Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc. Natl. Acad. Sci. USA. 1974;71:3971–3975. doi: 10.1073/pnas.71.10.3971. - DOI - PMC - PubMed

LinkOut - more resources